Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study)
British Journal of Dermatology · 20.06.2024 · 191 (1) · 143-144
DOI: 10.1093/bjd/ljae153 ↗Kurz gefasst
Leserbrief in der Zeitschrift British Journal of Dermatology, online erschienen am 25.04.2024. Verfasst von Sofia Tzoumpa und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Henri-Mondor University Hospital, AP-HP, Créteil, France. Hauptthemen laut MEDLINE: Sezary Syndrome, Antibodies, Monoclonal, Humanized, Skin Neoplasms, Disease Progression. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
The results of this study suggest that progressive discontinuation of mogamulizumab (Moga) should be considered once a response is obtained in patients with Sézary syndrome, even after a short treatment duration. This may minimize the risk of adverse effects, costs and resistance to Moga. Additionally, our study emphasizes that Moga rechallenge should be encouraged as a first choice in relapsing patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Henri-Mondor University Hospital, AP-HP, Créteil, France.
- Paris Est Créteil University, EpiDermE, Créteil, France.
- French Cutaneous Lymphomas Study Group (GFELC), France.
ORCID-Profile: Sofia Tzoumpa, Saskia Ingen-Housz-Oro, Maël Blanchard, Marie Beylot-Barry
Zitieren
APA
Tzoumpa, S., Ingen-Housz-Oro, S., de Masson, A., Pham-Ledard, A., El Aarbaoui, T., Dereure, O., Quereux, G., Faiz, S., de Vicq de Cumptich, M., Ram-Wolff, C., Janela-Lapert, R., Guenova, E., Lheure, C., Le Corre, Y., Adamski, H., Blanchard, M., Bonnet, N., Amatore, F., Grange, F., …, & Beylot-Barry, M. (2024). Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study). British Journal of Dermatology, 191(1), 143-144. https://doi.org/10.1093/bjd/ljae153
Vancouver
Tzoumpa S, Ingen-Housz-Oro S, de Masson A, Pham-Ledard A, El Aarbaoui T, Dereure O, et al. Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study). British Journal of Dermatology. 2024;191(1):143-144. doi:10.1093/bjd/ljae153
BibTeX
@article{Tzoumpa2024,
author = {Tzoumpa, Sofia and Ingen-Housz-Oro, Saskia and de Masson, Adèle and Pham-Ledard, Anne and El Aarbaoui, Tarik and Dereure, Olivier and Quereux, Gaëlle and Faiz, Sarah and de Vicq de Cumptich, Marine and Ram-Wolff, Caroline and Janela-Lapert, Raphaël and Guenova, Emmanuella and Lheure, Coralie and Le Corre, Yannick and Adamski, Henri and Blanchard, Maël and Bonnet, Nathalie and Amatore, Florent and Grange, Florent and Troin, Laura and Bagot, Martine and Beylot-Barry, Marie},
title = {Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study)},
journal = {British Journal of Dermatology},
year = {2024},
volume = {191},
number = {1},
pages = {143--144},
doi = {10.1093/bjd/ljae153}
}
EUVIMED